Dianthus Therapeutics shares are trading higher after the company announced FDA. clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
Portfolio Pulse from Benzinga Newsdesk
Dianthus Therapeutics shares are trading higher following the FDA clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
June 12, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dianthus Therapeutics shares are trading higher after the FDA cleared its Phase 2 IND application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
The FDA clearance for the Phase 2 IND application is a significant milestone for Dianthus Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100